• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Know Labs Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    10/30/24 5:26:06 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    knwn_8k.htm
    0001074828false--09-3000010748282024-10-252024-10-25iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 25, 2024

     

    KNOW LABS, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada

     

    001-37479

     

    90-0273142

    (State or other jurisdiction

    of incorporation)

     

    (Commission File Number)

     

    (IRS Employer

    Identification No.)

     

    619 Western Avenue, Suite 610, Seattle, Washington

     

    98104

    (Address of principal executive offices)

     

    (Zip Code)

     

    (206) 903-1351

    (Registrant’s telephone number, including area code) 

     

     _____________________________________________________

    (Former name or former address, if changed since last report.) 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001

     

    KNW

     

    NYSE American LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.                                                      

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On October 25, 2024, at a special meeting of the stockholders (the “Special Meeting”) of Know Labs, Inc. (the “Company”), the stockholders of the Company approved the adoption of an amendment to the Know Labs, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) in accordance with the voting results set forth below under Item 5.07. The 2021 Plan was originally approved by the Board of Directors of the Company (the “Board”) on August 12, 2021 and on October 15, 2021 the 2021 Plan was approved by our stockholders.

     

    At the Special Meeting, the stockholders approved an increase in the total number of shares of common stock available for issuance under the 2021 Plan to 40,000,000 shares plus (i) the number of shares added to the Plan pursuant to an automatic share increase provided for in Section 4.2 of the 2021 Plan and (ii) the sum of (A) any shares that, as of the date of stockholder approval of the 2021 Plan, have been reserved but not issued pursuant to any awards granted under the Company’s 2011 Plan, and (B) any shares subject to stock options or similar awards granted under the 2011 Plan that, after the date of stockholder approval of the 2021 Plan, expire or otherwise terminate without having been exercised in full and shares issued pursuant to awards granted under the 2011 Plan that are forfeited to or repurchased by the Company, with the maximum number of shares to be added to the 2021 Plan pursuant to clause (ii) equal to 7,592,825 (the “Plan Amendment”).  The Plan Amendment was previously approved by the Board on September 11, 2024 subject to stockholder approval and was approved by our stockholders on October 25, 2024.

     

    The primary purpose of the 2021 Plan is to attract and retain officers, employees and directors for our company and our subsidiaries; motivate them by means of appropriate incentives to achieve long-range goals; provide incentive compensation opportunities; and further align their interests with those of our stockholders through compensation that is based on our common stock. The 2021 Plan is administered by the Compensation Committee of the Board. The 2021 Plan provides for the issuance of awards consisting of: (a) incentive stock options, (b) non-qualified stock options, (c) stock appreciation rights, (d) restricted awards, (e) performance share awards, and (f) performance compensation awards.

     

    The above description of the 2021 Plan and the Plan Amendment does not purport to be complete, and is qualified in its entirety by reference to the full text of the 2021 Plan, as amended, a copy of which is attached hereto as Exhibit 10.1, and is incorporated by reference into this Item 5.02. The 2021 Plan is also described in detail in Proposal 2 of the Company’s Proxy Statement filed with the Securities and Exchange Commission on October 7, 2024, which summary is incorporated in its entirety herein by reference. 

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    As described under Item 5.07 of this Current Report on Form 8-K, on October 25, 2024 at the Special Meeting the stockholders of the Company approved a proposed amendment to the Company’s certificate of incorporation to increase the Company’s authorized shares of common stock from 200 million shares to 300 million shares (the “Amendment”). 

     

    The Amendment was filed with the Nevada Secretary of State on October 29, 2024, and became effective on that date. The full text of the Amendment is also filed herewith as Exhibit 3.1 and is incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On October 25, 2024, a Special Meeting of the stockholders the Company was held. As of September 12, 2024, the record date, there were 108,001,782 shares of common stock outstanding and 1,487,755 shares of common stock that can be voted on an as-if-converted basis from shares of preferred stock, for a total of 109,489,537 shares eligible to vote at this meeting. Proxies representing 63,149,072 shares have been signed and delivered.  This constitutes 57.7% of the total shareholders of the Company, which represents a quorum.   

     

    Each of the matters considered at the meeting was described in detail in the definitive proxy statement on Schedule 14A that the Company filed with the Securities and Exchange Commission on October 7, 2024.

     

     
    - 2 -

     

     

    Proposal No. 1 - Approved an amendment to our Articles of Incorporation to increase the number of authorized shares of Common Stock from 200 million to 300 million.

     

    Motion

    Description

     

    Vote

    Shares

    1

    Approve an amendment to our Articles of Incorporation to increase the number of authorized shares of Common Stock from 200 million to 300 million.

     

    For

    57,508,075

     

     

    Against

    5,428,192

     

     

    Withheld

    212,805

     

     

    Broker Non-Votes

    -

      

    Proposal No. 2 - To approve an amendment to the Know Labs, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2021 Plan to 40,000,000.

     

    Motion

    Description

     

    Vote

    Shares

    2

    Approve an amendment to the Know Labs, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2021 Plan to 40,000,000

     

    For

    19,743,756

     

     

    Against

    7,447,133

     

     

    Withheld

    335,707

     

     

    Broker Non-Votes

    35,622,476

     

    Proposal No. 3 - Approved to consider and vote upon adjournment of the Special Meeting in order to solicit additional proxies if there are not sufficient shares to be voted in favor of any of the foregoing proposals at the time of the Special Meeting.

       

    Motion 

    Description

     

    Vote

    Shares

    3

    Consider and vote upon adjournment of the Special Meeting in order to solicit additional proxies if there are not sufficient shares to be voted in favor of any of the foregoing proposals at the time of the Special Meeting

     

    For

    56,250,834

     

     

    Against

    6,072,649

     

     

    Withheld

    825,589

     

     

    Broker Non-Votes

    -

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No. 

     

    Description

     

     

     

    3.1

     

    Certificate of Amendment to Articles of Incorporation

    10.1

     

    2021 Know Labs Inc. Equity Incentive Plan, as amended

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     
    - 3 -

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 30, 2024

     

    KNOW LABS, INC.

     

     

     

     

     

     

     

    /s/ Ronald P. Erickson

     

     

     

    Name: Ronald P. Erickson

     

     

     

    Title: Chairman of the Board

     

     

     
    - 4 -

     

    Get the next $KNW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Know Labs, Inc. Announces Adjournment of Special Meeting of Stockholders

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has adjourned its Special Meeting of Stockholders (the "Special Meeting") scheduled for July 24, 2025 in order to provide stockholders additional time to vote on all proposals described in the Company's definitive proxy statement for the Special Meeting, filed with the Securities and Exchange Commission on June 30, 2025. The Special Meeting will be reconvened at 1:30 p.m. Pacific Time on Thursday, July 31, 2025 at the following url: www.virtualshareholdermeeting.com/KNW2025SM. The record date for the reconvened Special

    7/24/25 5:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Reminds its Stockholders to Vote Ahead of the Special Meeting on July 24

    Know Labs, Inc. (NYSE:KNW) ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today issued a reminder to its stockholders to vote ahead of the Special Meeting of Stockholders (the "Special Meeting") to be held virtually on Thursday, July 24, 2025 at 1:30 p.m. pacific time. The methods for voting and submitting proxies are described in the previously distributed proxy materials for the Special Meeting. The Company's Board of Directors encourages any stockholders as of the record date of June 20, 2025, who have not yet voted their shares for the Special Meeting, to cast their vote "For" each proposal, now. You may vote: over

    7/22/25 4:47:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

    Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

    6/6/25 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Jenkinson Linda

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:37:58 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 3 filed by new insider Jenkinson Linda

    3 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:30:18 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Chief Operating Officer Chapman Kirk

    4 - USBC, Inc. (0001074828) (Issuer)

    8/15/25 9:02:09 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    SEC Filings

    View All

    SEC Form DEF 14A filed by Know Labs Inc.

    DEF 14A - USBC, Inc. (0001074828) (Filer)

    8/26/25 3:24:34 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form D filed by Know Labs Inc.

    D - USBC, Inc. (0001074828) (Filer)

    8/21/25 4:53:44 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - USBC, Inc. (0001074828) (Filer)

    8/15/25 8:31:15 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    View All

    Know Labs Appoints Chris Somogyi as President, International

    Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

    5/16/24 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Medical and Scientific Advisory Board

    New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

    12/14/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs Expands Board of Directors

    Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

    11/8/23 9:00:00 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Financials

    Live finance-specific insights

    View All

    Know Labs, Inc. Reports Third Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

    8/14/23 4:15:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports Second Quarter FY2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

    5/15/23 4:05:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    Know Labs, Inc. Reports First Quarter 2023 Results

    Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

    2/14/23 4:00:00 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    6/3/24 2:11:39 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D filed by Know Labs Inc.

    SC 13D - KNOW LABS, INC. (0001074828) (Subject)

    10/25/23 7:27:11 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

    SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

    10/19/23 6:32:18 AM ET
    $KNW
    Industrial Machinery/Components
    Industrials